Israel Englander’s Millennium Management LLC increased its position in Intuitive Surgical Inc. (NASDAQ: ISRG) during the fourth quarter of 2025, according to Form 13F filings with the U.S. Securities and Exchange Commission. The move draws attention to one of healthcare’s most consistently profitable growth franchises — and to the risks facing it as the robotic surgery market matures.
As of April 10, 2026, Intuitive Surgical had a market capitalization of approximately $160.6 billion (Yahoo Finance, April 10, 2026).
Englander’s ISRG Position — 13F Filing Details
According to Millennium Management LLC’s 13F filing for the quarter ended December 31, 2025 (filed February 14, 2026), Millennium reported ownership of approximately 1,055,789 shares of Intuitive Surgical, an increase of approximately 205,377 shares — or about 24% quarter-over-quarter — from 850,412 shares held as of September 30, 2025. The market value of the position at quarter-end was approximately $489.8 million (SEC EDGAR, 2026).
Quarter End
Shares Held
Change (QoQ)
Est. Market Value
Q3 2025
850,412
—
~$343.7M
Q4 2025
1,055,789
+205,377 (+24%)
~$489.8M
Source: SEC EDGAR 13F filing, Millennium Management LLC, February 14, 2026.
Intuitive Surgical: Business Overview and Recent Performance
Intuitive Surgical designs, manufactures, and markets robotic-assisted surgical systems, principally the da Vinci Surgical System and the Ion endoluminal platform. Its revenue model is split between capital equipment sales and a high-margin recurring stream from instruments, accessories, and service contracts. As of the quarter ended December 31, 2025, recurring revenue sources represented approximately 76% of total quarterly revenue (Intuitive Surgical IR, 2026).
For Q4 2025, Intuitive Surgical reported GAAP revenue of $2.87 billion, a 14% increase year-over-year. GAAP net income was $913.6 million, up from $794.3 million in Q4 2024 — a 15.0% increase. The installed base of da Vinci systems expanded to 8,810 units worldwide at year-end 2025, from 8,105 units at year-end 2024. Global da Vinci procedures grew 18% year-over-year in Q4 2025 (Intuitive Surgical IR, Q4 2025).
Metric
Q4 2025 (GAAP)
Q4 2024 (GAAP)
YoY Change
Revenue
$2.87B
$2.52B
+14%
Net Income
$913.6M
$794.3M
+15.0%
Installed Base (units)
8,810
8,105
+8.7%
Procedure Growth
+18% YoY
+19% YoY
–1 ppt
Why Institutions Are Watching ISRG
Intuitive Surgical’s appeal to institutional investors rests on its dominant competitive position, high recurring revenue mix, and a cash-rich balance sheet with no long-term debt. The company ended Q4 2025 with approximately $9.03 billion in cash and equivalents (Intuitive Surgical IR, 2026).
Analyst sentiment as of April 10, 2026 remains constructive. Per Yahoo Finance, 19 of 30 covering analysts rate ISRG as Strong Buy, with a consensus 12-month price target of $619.85. Based on a closing price of $452.07 on April 10, 2026, that target implies an upside of approximately 37.1% ($452.07 base; $619.85 / $452.07 – 1 = 37.1%). The stock trades at a trailing twelve-month GAAP P/E of approximately 57.4 (Yahoo Finance, April 10, 2026).
The competitive moat rests on several factors: an installed base of over 8,800 systems creates high switching costs for hospitals; the procedural volume required to justify system investment trains surgeons on the da Vinci platform, deepening lock-in; and a broad portfolio of regulatory clearances across geographies makes it difficult for new entrants to gain traction quickly. That said, competitive pressures are intensifying in China, where domestic manufacturers are introducing lower-cost platforms and regulatory changes allow greater use of remanufactured instruments.
Management guided for 2026 da Vinci procedure growth of 13%–15%, a step down from 18% in 2025, reflecting both pandemic normalization and intensifying competition. Adjusted gross margins are expected in the 67%–68% range, with a management-cited ~1.2% tariff impact on revenues. Operating expenses are projected to grow 11%–15% in 2026 (Intuitive Surgical IR, 2026).
Key Signals for Investors
The guided deceleration from 18% to 13%–15% procedure growth in 2026 is the most important number to track — if actual growth lands below the bottom of that range, it signals structural pressure on the core revenue engine rather than normalization (Intuitive Surgical IR, 2026).
Tariff headwinds and a projected 11%–15% increase in operating expenses will weigh on margins in the near term; Intuitive Surgical’s ability to offset these pressures through pricing and cost discipline will determine whether the premium valuation holds.
Rising domestic competition in China — historically a high-growth region — represents the single most underpresented risk in consensus models; investors should monitor market share data in Asia-Pacific when Q1 2026 results are reported on April 21, 2026.
The $9+ billion net cash position provides Intuitive Surgical with flexibility to pursue tuck-in acquisitions, further international distribution buildouts, or return capital — any strategic deployment of that cash could be a near-term re-rating catalyst.
With a TTM GAAP P/E above 57 and forward P/E of approximately 45, execution risk is elevated; even a modest guidance reduction could result in meaningful multiple compression at current prices (Yahoo Finance, April 10, 2026).
